ACRIN-NSCLC-FDG-PET

Positron Emission Tomography Pre- and Post-treatment Assessment for Locally Advanced Non-small Cell Lung Carcinoma

This was a multicenter clinical trial by the ACRIN Cooperative Group (now part of ECOG-ACRIN) and the RTOG Cooperative Group (now part of NRG) using FDG-PET imaging both pre- and post-chemoradiotherapy.

The objective of the ACRIN 6668 multi-center clinical trial was to determine if the PET standardized uptake value (SUV) measurement from FDG-PET imaging shortly after treatment is a useful predictor of long-term clinical outcome (survival) after definitive chemoradiotherapy. Eligible patients were those older than 18 years with AJCC-criteria clinical stage IIB/III non-small cell lung carcinoma who were being planned for definitive concurrent chemoradiotherapy (inoperable disease).

Primary Aim Findings: Higher post-treatment tumor SUV (SUVpeak, SUVmax) is associated with worse survival in stage III NSCLC, although a clear SUV cutoff value for routine clinical use as a prognostic factor was uncertain [1]. Later analyses found that larger pre-treatment metabolic tumor volumes (MTVs) were associated with significantly worse overall survival [2]. Other secondary analyses found potentially predictive image texture biomarkers.

Study Design Summary: Patients received conventional concurrent platinum-based chemoradiotherapy without surgery; post-radiotherapy consolidation chemotherapy was allowed. A baseline whole-body FDG-PET scan was performed prior to therapy. A second post-treatment whole-body FDG-PET scan occurred approximately 14 weeks after radiotherapy (at least 4 weeks after adjuvant chemotherapy).

Pre-treatment FDG-PET scans were performed on ACRIN-qualified scanners. Post-treatment FDG-PET scans were required to be performed within 12–16 weeks after completion of therapy, using the same scanner as that used for the pre-treatment scans.

Acknowledgements

This shared data set was provided in collaboration with the American College of Radiology Core Lab. Many thanks are due to the ACRIN 6668 trial team, and all the patients participating in the study.

This study was supported by the ACRIN Cooperative Group (now part of ECOG-ACRIN) and the RTOG Cooperative Group (now part of NRG) which received funding from the National Cancer Institute through UO1 CA080098 and UO1 CA079778.

資料與資源

此資料集沒有資料

額外的資訊

欄位
最後更新 十二月 3, 2019, 14:28 (CST)
建立 二月 14, 2019, 10:19 (CST)

推薦資料集:


  • 境外基金市場資訊-投資區域別

    付費方式 免費
    更新頻率 不定期
    境外基金市場資訊-投資區域別(臺灣集中保管結算所)
  • 林務局所轄自然步道軌跡圖-140_都蘭山步道

    付費方式 免費
    更新頻率 不定期
    提供林務局所轄自然步道軌跡圖-140_都蘭山步道KMZ下載檔案。
  • 國立臺灣科學教育館大眾科學講座

    付費方式 免費
    更新頻率 不定期
    大眾科學講座介紹現今社會大眾吸收科學知識的途徑相當多元,包括書籍、雜誌、新聞報導、電視媒體等等,但當產生疑惑時,卻無法及時發問,仍需憑藉自己的力量尋求解答,也降低了科學教育推廣的效力;若要克服上述的困難,讓民眾能再吸收知識的同時,自身的問題也能獲得解答,舉辦科普講座,著實為一種有效推廣科學教育的形式。本館身負著科學教育向下紮根的重要使命,為配合教育部推...
  • 基隆市最近五年契稅綜合統計表

    付費方式 免費
    更新頻率 不定期
    集中列示於政府資料開放平台資料集之詮釋資料,包含契稅應稅及免稅之件數、契價、稅額
  • 20531-02-01-2 臺中市營造業家數及資本額

    付費方式 免費
    更新頻率 不定期
    2015-2017年臺中市營造業家數及資本額資料